Undeclared Drug Ingredients in Herbal Supplements: Why Supplier COAs Aren't Enough

In 2023 alone, FDA issued more than 130 warning letters to dietary supplement companies for products containing undeclared pharmaceutical ingredients. Many of those brands had supplier certificates of analysis on file. Several had passed internal GMP audits just months prior. Most believed their raw materials were clean.

They were wrong.

The adulterants were there — sildenafil analogs in “male enhancement” formulas, sibutramine in weight-loss blends, stimulant compounds in pre-workout powders marketed as all-natural. The COA didn’t catch any of it. And that’s not a knock on documentation as a practice. COAs serve a legitimate function in the supply chain. But there’s a meaningful gap between what a standard certificate of analysis actually certifies and what independent adulteration screening at an analytical testing lab can detect — and that gap is where FDA enforcement tends to find brands standing exposed.

What a Standard Supplier COA Actually Tests (And What It Doesn’t)

Most ingredient suppliers provide COAs covering four parameters: declared identity, purity percentage, heavy metals in broad concentration tiers, and microbial limits. Some include moisture content or residual solvents. The better-quality suppliers add HPTLC or TLC chromatograms for botanical ingredients.

None of that is adulteration screening.

A COA confirms that the material matches a reference standard for the declared ingredient. It doesn’t scan the extract for 40 to 100 pharmaceutical analogs using LC-MS/MS. It doesn’t flag synthetic cannabinoids. It doesn’t catch a designer stimulant added at sub-threshold concentrations specifically to boost perceived product efficacy without triggering label obligations.

And here’s something that rarely comes up in supplier pre-qualification calls: a significant portion of COAs on the market are self-issued by the supplier. Independent, third-party-verified COAs are still the exception rather than the rule for raw materials sourced from overseas suppliers operating without ISO 17025 accreditation.

Under 21 CFR Part 111 — the GMP standard governing dietary supplement manufacturing — brands are required to establish identity specifications for every dietary ingredient and verify those specifications before use. The regulation doesn’t prescribe a specific analytical method. It doesn’t mandate LC-MS/MS or any other technique. But when FDA arrives after a consumer adverse event and finds pharmaceutical adulterants in your finished product, “we relied on our supplier’s COA” is not a position that tends to hold under scrutiny.

How Adulteration Screening Works in an Analytical Testing Lab

Full-panel adulteration screening is what separates a passive documentation check from an active quality defense.

A properly equipped chemical testing laboratory runs several complementary methods:

LC-MS/MS (Liquid Chromatography–Tandem Mass Spectrometry) is the gold standard for pharmaceutical adulterant detection. A single method can simultaneously screen for 50–100 target compounds — PDE5 inhibitors (sildenafil, tadalafil, and their structural analogs), sibutramine and its metabolites, stimulants like DMAA and phenethylamines, anabolic steroids, and diuretics. Detection limits typically run in the 1–5 ppb range, which matters precisely because adulterants are often deliberately added at sub-labeling thresholds.

HPTLC (High-Performance Thin-Layer Chromatography) is particularly useful for botanical ingredients. Running a dried extract against a validated HPTLC fingerprint library can confirm species identity and flag substitution adulterants — an echinacea product using the wrong Echinacea species, a ginger extract cut with Curcuma material. The American Herbal Pharmacopoeia and USP have published validated HPTLC reference methods for more than 200 botanicals, so there’s a solid foundation of reference data to work from.

DNA Barcoding fills the gap for chopped or powdered botanical materials where morphological identification is simply not possible. Using ITS2 or rbcL genetic markers, a qualified lab can confirm species identity at a forensic level. It’s not a replacement for chemical fingerprinting — you can have the correct plant and still have pharmaceutical adulterants present — but for catching botanical substitution in complex, processed raw materials, it’s indispensable.

High-Resolution Mass Spectrometry (HRMS) with non-targeted screening is the tool you reach for when you don’t know what you’re looking for. Unlike targeted panels, HRMS with database matching flags unknown compounds above a defined mass threshold and allows retrospective re-analysis as new adulterant structures emerge. This is how analytical laboratories identify novel designer adulterants that aren’t yet in any targeted panel.

Brands that run these tests as part of incoming raw material qualification catch problems before batch release. The brands that skip them often find out the hard way — through an adverse event report, an FDA inspection, or a marketplace notice from a retailer’s third-party compliance program.

The Three Raw Material Categories With the Highest Adulteration Risk

Not all ingredients carry the same risk. Based on FDA’s own published enforcement data and independent surveillance literature, three categories consistently show the highest rates of undeclared pharmaceutical adulterants:

Sexual enhancement botanicals: FDA has identified more than 550 products over the past decade containing undeclared PDE5 inhibitors. Critically, these aren’t always sildenafil itself — suppliers of illicit blends frequently use structural analogs like hongdenafil, aildenafil, or xanthoanthrafil specifically because they fall outside the coverage of older standard analytical panels. If your product includes any botanical marketed for male enhancement — tribulus terrestris, maca, epimedium — your incoming raw material carries elevated adulteration risk regardless of the finished-product category claim.

Weight loss formulas: Sibutramine, withdrawn from the U.S. market in 2010 due to cardiovascular risk, continues to appear in weight-loss supplement raw materials sourced from certain origins. Phentermine and fenfluramine analogs also show up. A 2021 NSF International surveillance study found pharmaceutical adulterants in roughly 20% of weight-loss products tested from online marketplaces. That figure applies to finished products, but the contamination almost always originates at the raw material or contract manufacturer level.

Pre-workout and sports nutrition blends: Stimulant adulterants here include DMAA (1,3-dimethylamylamine), DMBA, methylsynephrine, oxilofrine, and tuaminoheptane. Some are undeclared intentionally to boost energy effects; others reflect genuine contamination from shared facilities or mislabeled raw material shipments. Either way, the brand sourcing the ingredient carries the regulatory liability under 21 CFR Part 111.

Even if your formulas don’t fall squarely into these three categories, it’s worth auditing whether your ingredient list intersects with them — shared botanical extracts, shared processing pathways, shared suppliers who serve multiple market segments.

Building a Raw Material Testing Program That Fits Your Operation

Most brands either test everything uniformly or test almost nothing, and both extremes waste resources. A risk-stratified approach — informed by ingredient category, supplier qualification history, and country of origin — lets quality teams direct their analytical testing lab budget where the exposure is highest.

A practical three-tier framework:

Tier 1 — Test every incoming lot, full panel: Ingredients in the three high-risk categories above. Any botanical extract from a supplier without a verified third-party audit history. Any new supplier, regardless of category or geography.

Tier 2 — Test every third lot, or quarterly: Established suppliers with six or more consecutive clean test results. Ingredients outside high-risk categories but with complex multi-step processing. Any supplier where you’ve seen one borderline result in the past 12 months.

Tier 3 — Annual verification plus COA review: Simple commodity ingredients with strong audit history, long-standing supplier relationships, and low pharmacological activity. Ongoing supplier qualification should trigger an escalation to Tier 1 if any anomaly surfaces.

The typical turnaround for a full incoming panel — identity, adulteration screen, heavy metals, microbiology — runs 5–7 business days from the time samples arrive with complete lot documentation. That’s not a bottleneck if testing is built into the sourcing schedule. At our Chicago-area sample receiving hub, we regularly see lots arrive the same week they’re earmarked for blending. That compression makes thorough screening nearly impossible. Brands that maintain a two-week incoming testing buffer are the ones who can respond to a failed screen without triggering a production crisis.

The Real Cost of Skipping Adulteration Screening

Let’s be direct about the downstream consequences.

FDA can initiate a mandatory recall. Under the Food Safety Modernization Act, the agency can mandate action for Class I recalls — products with a reasonable probability of causing serious adverse health consequences. That category is not rare for pharmaceutical adulterant cases. In 2024, multiple supplement-related Class I recalls were tied directly to undeclared pharmaceutical ingredients across sexual enhancement, weight loss, and sports nutrition.

Beyond the recall itself: legal fees, third-party re-testing, retailer chargebacks, destroyed inventory, and reputational damage that outlasts the actual product. A comprehensive adulteration screen at a qualified analytical testing lab typically runs $350–$800 per raw material sample, depending on the panel scope and number of target compounds. Run that number against the cost of a single recall — often exceeding $500,000 once logistics, legal, and brand remediation are factored in — and the math becomes straightforward.

One Concrete Step Before Your Next Purchase Order

Before your next raw material purchasing order, pull your current active supplier list and sort it by category risk using the framework above. For every Tier 1 ingredient on that list, verify that the most recent received lot was independently tested by a qualified analytical testing laboratory — not self-certified by the supplier. If it wasn’t, flag it for third-party incoming testing before it enters your production schedule.

That’s the minimum defensible position. For brands distributing on Amazon, in natural retail, or into any channel where third-party compliance programs are active and tightening, it’s also the floor — not the ceiling — of what a robust quality program looks like.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Ship your sample to our Chicago facility — get a Qalitex CoA in 5–7 days. Contact us

Related from our network

• ISO 17025-Accredited Supplement & Raw Material Testing — Qalitex Laboratories runs full-panel adulteration screens, heavy metals, and botanical identity testing under ISO 17025 accreditation, with results issued as independently verified COAs.